Final review of ADLIFE, European project coordinated by Biosistemak
After five years of work, important milestones have been reached in the personalised care of people with advanced chronic diseases.
On 18 February 2025, the final review meeting of the European project ADLIFE, coordinated by Biosistemak, was held, marking the culmination of almost five years of innovative work in the field of integrated and personalised care for elderly people with advanced chronic diseases.
This project, funded by the European Union’s Horizon 2020 programme, has made significant progress in the development of digital tools for the creation and management of personalised care plans, the implementation of patient empowerment platforms and the deployment of clinical decision support systems.
The ADLIFE project has piloted interventions in six European regions, including the Basque Country (Spain), Israel, Denmark, England, Germany and Scotland. During the final meeting, the overall results of the project were presented, highlighting the progress in each work package and the impact generated in the participating countries. The achievements of the last reporting period, from May 2023 to November 2024, were emphasised and lessons learned in the implementation of ADLIFE solutions were shared.
Among the main milestones and conclusions of the project, the flexibility of the ADLIFE integrated care model stands out, which has allowed its successful implementation and replication in different healthcare contexts. In addition, ADLIFE has demonstrated improvements in the health status and autonomy of patients, favouring their empowerment. At the organisational level, the project has optimised the use of resources, demonstrating the positive impact of digital solutions on the efficiency of the healthcare system. These results reinforce the potential of digital transformation in improving integrated care for people with advanced chronic diseases.
Role of Biosistemak and Euskadi in ADLIFE
Biosistemak has played a crucial role in the ADLIFE project as the main coordinator at European level. Our institute has led the management of the consortium, the evaluation of results and the general coordination of the project, including an active participation in the exploitation plan of the results.
In the Basque Country, Biosistemak and Osakidetza have collaborated closely in the implementation of the local pilot. Osakidetza drove the implementation of the pilot in the Basque Country, while Biosistemak coordinated its development, ensuring an effective collaboration between both entities. During the final meeting, the lessons learned and benefits obtained were presented, highlighting concrete long-term actions such as improved coordination of care and the empowerment of patients in the management of their health.
The experience and joint leadership of Biosistemak and Osakidetza have been fundamental to the success of the project
ADLIFE’s Future and Legacy
The success of ADLIFE not only marks the successful completion of the project, but also lays the foundations for future innovations in personalised and digital healthcare, consolidating the position of Biosistemak and Euskadi as leaders in the research and implementation of advanced solutions in healthcare systems.
Following the completion of the project, several scientific publications are planned to disseminate the findings and lessons learned. Work is currently underway on several articles addressing the results of the project evaluation, the experience of the pilots and the challenges associated with the deployment and implementation of ADLIFE in different healthcare settings. These publications will include key recommendations to facilitate the adoption of digital solutions in the care of people with advanced chronic diseases.
In addition, work has been done to ensure the continuity and sustainability of ADLIFE solutions, exploring their integration into regional and European health systems and seeking additional funding opportunities to scale up their implementation.
These actions will ensure that ADLIFE’s impact extends beyond its official duration, contributing to the continuous improvement of care for people with advanced chronic diseases across Europe.
